Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615001119583p
Ethics application status
Submitted, not yet approved
Date submitted
18/09/2015
Date registered
23/10/2015
Date last updated
23/10/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
Target Temperature Management for Traumatic Brain Injury:
A Feasibility Study of Pyrexia Control
Scientific title
A feasibility study on the effect of target temperature management on patient temperature in traumatic brain injury patients.
Secondary ID [1] 287502 0
Nil
Universal Trial Number (UTN)
Trial acronym
TTM-TBI-Feasibility
Linked study record

Health condition
Health condition(s) or problem(s) studied:
traumatic brain injury 296256 0
Condition category
Condition code
Neurological 296525 296525 0 0
Other neurological disorders
Injuries and Accidents 296526 296526 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
1. If a patient has an initial temperature below 36.0 degrees celsius, the patient will be managed according to the preference of the treating clinician until temperature reaches 36.0 degrees celsius.
2. The intervention will be initiated when temperature reaches 36.0 degrees celsius
3. The aim is to control temperature to 36.0 degrees celsius, with the intention of avoiding any core temperature greater than or equal to 37.0 degrees celsius.
4. The minimum duration is 72 hours following randomisation or when mechanical ventilation is ceased, whichever occurs first.
5. The intervention may be maintained for as long as is clinically indicated at the discretion of the treating clinician.
6. The choice of intervention (physical cooling device) is at the discretion of the treating clinician.
7. Adherence will be monitored by recording hourly core temperature and use of physical cooling.
Intervention code [1] 292887 0
Treatment: Other
Comparator / control treatment
Standard care: no specific guidelines will be provided on temperature management and treatment of pyrexia will occur according to clinical discretion.
Control group
Active

Outcomes
Primary outcome [1] 296154 0
Mean temperature difference between the intervention and standard care groups.

All patients will have temperature monitored hourly using intravesical temperature (bladder catheter). In oliguric patients (defined as urine output < 0.3mls/kg/hr for greater than 4 hours) or patients with an open abdomen, core temperature will be measured with intravascular, oesophageal, nasopharyngeal or rectal temperature measurement.
Timepoint [1] 296154 0
Hourly intravesical (bladder) temperature during the first 72 hours after randomisation.
Secondary outcome [1] 317640 0
For patients that are receiving intracranial pressure monitoring as part of their standard clinical care, we will calculate mean intracranial pressure difference between the intervention and standard care groups.

Intracranial pressure will be monitored in this study with an intraparenchymal catheter or an external ventricular drain.
Timepoint [1] 317640 0
In patients with a clinical indication for intracranial pressure monitoring, Intracranial pressure will be monitored hourly during the first 72 hours after randomisation or the end of mechanical ventilation.
Secondary outcome [2] 317641 0
Duration of mechanical ventilation.

This will be determined by review of the hospital medical record.
Timepoint [2] 317641 0
From randomisation to removal of the endotracheal tube and absence of re-intubation or non invasive ventilation for 24 hours after removal (survivors and non-survivors will be reported separately).

Eligibility
Key inclusion criteria
1. Age greater than or equal to 16
2. Blunt trauma with clinical diagnosis of TBI defined as:
a. Blunt head trauma
b. Glasgow Coma Scale (GCS) score less than or equal to 13 (prior to sedation)
c. Computed tomographic (CT) scan of the head consistent with traumatic brain injury
3. Invasive mechanical ventilation and predicted need for invasive mechanical ventilation beyond the next calendar day.
4. Screening and randomisation within 24 hours of injury
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. The treating physician intends to control temperature and/or induce hypothermia as part of the management plan
2. The treating clinician deems participation is not in the patient’s best interests
3. Drug or alcohol intoxication is likely to be the predominant cause of coma
4. Cardiac arrest at scene of injury
5. Spinal cord injury with confirmed neurological deficit
6. Pregnancy
7. Disability prior to injury, defined by a score of 4 or less as assessed by the extended Glasgow Outcome Score
8. Death is deemed to be imminent/inevitable or a treatment limitation order is in place
9. The patient has an underlying process or comorbidity making 180-day survival unlikely

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients with an admission diagnosis that includes TBI that are admitted to the participating ICU are eligible for screening and evaluation for enrolment into the study. All screened patients will be entered into the screening log whether or not the patient is randomised into the study.

The study will include all patients admitted to a participating intensive care unit who fulfill all the inclusion criteria and for whom none of the exclusion criteria exist.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation codes will be used, with stratification by study site and permuted blocks. Allocation concealment will be maintained by the use of sequentially numbered opaque envelopes.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The main analyses will be conducted on an intention to treat basis using standard statistical approaches for categorical and continuous data. The difference in the 72-hour temperature curves in patients randomised to the intervention group compared to the control group will be analysed using a repeated-measure linear model with generalised estimating equations to model within-patient correlations. The model will include fixed effects of treatment and time as well as baseline temperature as covariate. The primary analysis will include all available data without imputation.

A statistical analysis plan will be agreed upon prior to entry of data into the electronic database and prior to any analyses being conducted.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 4363 0
St George Hospital - Kogarah
Recruitment hospital [2] 4364 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 4365 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [4] 4366 0
Royal Brisbane & Womens Hospital - Herston
Recruitment outside Australia
Country [1] 7174 0
New Zealand
State/province [1] 7174 0
Wellington

Funding & Sponsors
Funding source category [1] 292075 0
Charities/Societies/Foundations
Name [1] 292075 0
Intensive Care Foundation (Application in progress)
Country [1] 292075 0
Australia
Primary sponsor type
Other
Name
The George Institute for Global Health
Address
The Division of Critical Care and Trauma
The George Institute for Global Health
Level 13, 321 Kent St, Sydney, NSW 2000, Australia
Country
Australia
Secondary sponsor category [1] 290753 0
Hospital
Name [1] 290753 0
St. George Hospital Clinical School
Address [1] 290753 0
Pitney Building, 2 Chapel St, Kogarah NSW 2217
Country [1] 290753 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 293559 0
Royal Prince Alfred Hospital Ethics Committee
Ethics committee address [1] 293559 0
Ethics committee country [1] 293559 0
Australia
Date submitted for ethics approval [1] 293559 0
14/09/2015
Approval date [1] 293559 0
Ethics approval number [1] 293559 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 60458 0
Dr Manoj Saxena
Address 60458 0
Division of Critical Care and Trauma
The George Institute for Global Health,
Level 13, 321 Kent Street, Sydney NSW 2000.
Country 60458 0
Australia
Phone 60458 0
+61296570348
Fax 60458 0
Email 60458 0
Contact person for public queries
Name 60459 0
Manoj Saxena
Address 60459 0
Division of Critical Care and Trauma
The George Institute for Global Health,
Level 13, 321 Kent Street, Sydney NSW 2000.
Country 60459 0
Australia
Phone 60459 0
+61296570348
Fax 60459 0
Email 60459 0
Contact person for scientific queries
Name 60460 0
Manoj Saxena
Address 60460 0
Division of Critical Care and Trauma
The George Institute for Global Health,
Level 13, 321 Kent Street, Sydney NSW 2000.
Country 60460 0
Australia
Phone 60460 0
+61296570348
Fax 60460 0
Email 60460 0

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseInterventions to reduce body temperature to 35 C to 37 C in adults and children with traumatic brain injury.2020https://dx.doi.org/10.1002/14651858.CD006811.pub4
N.B. These documents automatically identified may not have been verified by the study sponsor.